Uncovering Key Insights on Repligen – A Must-Know for Investors

By Emilio Sanchez • Friday, November 15 15:12 • Permanent Link

One of the losers of today's trading session was Repligen. Shares of the Biotechnology company plunged -14.2%, and some investors may be wondering if its price of $122.18 would make a good entry point. Here's what you should know if you are considering this investment:

Repligen has moved -5.4% over the last year, and the S&P 500 logged a change of 31.8%
RGEN has an average analyst rating of buy and is -36.45% away from its mean target price of $192.25 per share
Its trailing earnings per share (EPS) is $-0.3
Repligen has a trailing 12 month Price to Earnings (P/E) ratio of -407.3 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.78 and its forward P/E ratio is 68.6
The company has a Price to Book (P/B) ratio of 3.44 in contrast to the S&P 500's average ratio of 4.74
Repligen is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.